J&J rounds out the year with twin buy­outs, gain­ing con­trol of de­liv­ery and sur­gi­cal ro­bot­ics tech

J&J is scoop­ing up one of Bris­tol-My­ers-Squibb’s biotech part­ners spe­cial­ized in blad­der bi­ol­o­gy, with a par­tic­u­lar­ly keen in­ter­est in a tech­nol­o­gy that re­leas­es can­cer drugs lo­cal­ly.

The phar­ma gi­ant isn’t look­ing to make a splash here — the fi­nan­cial terms re­main undis­closed — but they are clear that they see a po­ten­tial for Taris’ sil­i­cone-based drug de­liv­ery de­vice far be­yond blad­der can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.